These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35929166)

  • 1. [Analysis on the Quality Status of in Vitro Diagnostic Reagents for National Medical Device Supervision and Inspection in 2020].
    Li X; Zhang X; Hao Q; Zhu J; Hong W
    Zhongguo Yi Liao Qi Xie Za Zhi; 2022 Jul; 46(4):459-463. PubMed ID: 35929166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis on the Characteristics of Quality Variation of National Medical Device Supervision and Inspection in 2020].
    Li X; Zhang XT; Hao Q; Zhu J; Ma JZ; Yang GJ
    Zhongguo Yi Liao Qi Xie Za Zhi; 2022 May; 46(3):326-331. PubMed ID: 35678446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Discussion on Supervision and Sampling of Biochemical Test Kits].
    Huang Y; Wu J
    Zhongguo Yi Liao Qi Xie Za Zhi; 2022 Mar; 46(2):216-218. PubMed ID: 35411754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of Quality Status of National Medical Device Supervision and Inspection in 2019].
    Li X; Zhang X; Hao Q; Zhu J; Ma J
    Zhongguo Yi Liao Qi Xie Za Zhi; 2021 Feb; 45(1):85-89. PubMed ID: 33522184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of Quality Status of National Medical Device Supervision and Inspection from 2013 to 2016].
    Zhang X; Hao Q; Shi X; Zhu J; Luo Q; Zhang Q; Cheng S
    Zhongguo Yi Liao Qi Xie Za Zhi; 2017 May; 41(3):216-219. PubMed ID: 29862772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk Point Analysis of Product Quality and Safety in Sample Inspection of National Medical Device Supervision].
    Hao Q; Zhang X; Zhu J; Shi X; Li X; Zhu N
    Zhongguo Yi Liao Qi Xie Za Zhi; 2019 May; 43(3):209-213. PubMed ID: 31184081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of Variety Selection for Medical Device Supervision and Inspection].
    Shi X; Zhang X; Zhu J; Hao Q; Li X
    Zhongguo Yi Liao Qi Xie Za Zhi; 2019 May; 43(3):202-204. PubMed ID: 31184079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discussion on Technical Evaluation Requirements of Allergen Detection Reagent Pre-marketing].
    Yang XH; Dong QF; Zhang L; Wang YH; Zhu WW
    Zhongguo Yi Liao Qi Xie Za Zhi; 2022 May; 46(3):318-322. PubMed ID: 35678444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis and Suggestions on Status Quo of Commissioned Production under Medical Device Marketing Authorization Holder System in China].
    Xing B; He T; Zhang D; Liang Y
    Zhongguo Yi Liao Qi Xie Za Zhi; 2022 Mar; 46(2):195-199. PubMed ID: 35411750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Discussion on Regulatory Risk of in Vitro Diagnostic Reagents in Use].
    Li Z; Jiang H; Wang J; Shen J
    Zhongguo Yi Liao Qi Xie Za Zhi; 2018 Jan; 42(1):62-63. PubMed ID: 29862751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A pilot study on the quality management system of in-vitro diagnostic reagents].
    Liu X; Huang JH; Xu FL; Wang Z; Gu WK
    Zhongguo Yi Liao Qi Xie Za Zhi; 2006 May; 30(3):199-205. PubMed ID: 16929780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Statistical analysis on findings in the quality management system during inspection of IVD manufactures of China].
    Tian S
    Zhongguo Yi Liao Qi Xie Za Zhi; 2012 Nov; 36(6):433-7. PubMed ID: 23461121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of reagents for infection testing: results of the market surveillance by the Federal Institute for Drugs and Medicinal Devices until end 2006.
    Siekmeier R; Halbauer J; Mientus W; Wetzel D
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():629-43. PubMed ID: 19218690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Software as medical devices/medical apps : Tasks, requirements, and experiences from the point of view of a competent authority].
    Terhechte A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Mar; 61(3):321-327. PubMed ID: 29318338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The current situation and suggestions on the institutes for medical devices test in China].
    Yang X; Li X; Mu R; Wang C; Li J
    Zhongguo Yi Liao Qi Xie Za Zhi; 2014 Jan; 38(1):57-60. PubMed ID: 24839853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on Risk Assessment Model of in
    Zhu Q; Ding J; Ren W; Mao Y; Wang W
    Zhongguo Yi Liao Qi Xie Za Zhi; 2019 Mar; 43(2):136-139. PubMed ID: 30977615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Explored the Function of Electromagnetic Compatibility (EMC) of Medical Devices from the Perspective of Test].
    Gao Z; Xu M; Zhang W; Liu Y; Cao X; He H
    Zhongguo Yi Liao Qi Xie Za Zhi; 2023 Jul; 47(4):442-444. PubMed ID: 37580298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Brief Discussion on the in Vitro Diagnostic Reagent Inspection Practice of
    He T; Chu S; Xie J
    Zhongguo Yi Liao Qi Xie Za Zhi; 2023 May; 47(3):324-327. PubMed ID: 37288638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Consideration and Practice of Introducing Third-party Certification Institutions to Participate in Post-marketing Supervision of Medical Devices].
    Lin S; Li Y; Mu Y
    Zhongguo Yi Liao Qi Xie Za Zhi; 2019 Nov; 43(6):442-446. PubMed ID: 31854533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.